The hemi-hydrate form of the cerebral function enhancing agent 1-[[1-[2-(trifluoromethyl)-4-pyrimidinyl]-4-piperidinyl]-methyl-2-pyrrolid inone, or BMY-21502 as it is more commonly designated, is an improved form of drug substance having equivalent biopharmaceutical properties compared to the known anhydrous form but providing cost, safety and ecological advantages in manufacture over the known anhydrous form.
脑功能增强剂1-[[1-[2-(三
氟甲基)-4-
嘧啶基]-4-
哌啶基]-甲基-2-
吡咯酮的半
水合物形式,常被称为BMY-21502,是一种改进的药物物质,具有与已知无
水形式相当的
生物制药特性,但在制造过程中提供了成本、安全和生态方面的优势。